News

The Race for the five digital banking licenses heats up further as more consortiums and companies announced their application, including ride-hailing giant Grab-Singtel consortium, which bagged a digital full-bank license in Singapore last year. These consortiums also include overseas investors and technology partners from Singapore, Japan, and China.

The funding will go towards scaling their team in Singapore, relocating their new headquarters, focus on growth in Southeast Asia and increased support for cross chain interoperable Digital ID applications.

We are extremely focused on accelerating our growth of pet owner acquisition in Malaysia and constantly experimenting with new growth channels to scale our business. Within the coming months, we hope to also further develop our proprietary technology which will allow us to distribute our product and manage our claims services smartly and at scale. To…

Besides Taiwan, 3 SQUARE is looking to expand into Hong Kong, Singapore, Malaysia, Thailand, Indonesia, The Philippines and Japan.

The startup seeks to tap into a growing opportunity in the retail investing space in Vietnam. The country of 97 million population has more than 75 percent internet users transacting money digitally, but only roughly 3.14 million--or 3.2 percent of the population-- investing in securities.

KLAR plans to use the funding for four business goals including R&D development to achieve economies of scale and treatment optimization, expand the company's talent base, enhance branding, and venture into complementary product offerings

Following the fundraise, WeMaintain also announced the opening of its Asia-Pacific headquarters in Singapore.

Eligible users will be able to split purchases over three equal, interest-free installments. Repayments will be automatically drawn every month, with no fees charged for on-time payments. In addition, customers will earn up to 10 percent cashback with every purchase.

Fairbanc's proprietary data science and machine learning platform leverages supply-chain data of FMCG distributor partners which allows financial institutions to assess credit risk and extend working capital to MSMEs with limited credit history and collaterals, according to the disclosure.

Proceeds from the funding will be used to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities, the company added.